The company will use the funds to advance delafloxacin, a differentiated fluoroquinolone, through an ongoing Phase 3 study to the submission of a new drug application in late 2014.
Melinta added that the proceeds will also support delafloxacin’s two ongoing Phase 3 trials for the treatment of acute bacterial skin and skin structure infections and and the selection of lead candidates from its RX-04 research program.
Executive director of Vatera Tom Koestler said, “We have seen real progress in this exceptional management team’s advancement of delafloxacin in terms of both its R&D and commercial strategy.
“We are committed to continuing to support Melinta and fostering the company’s growth into a strong and successful company with the potential near-term approval and launch of delafloxacin in 2015 as the foundation of this success.”
Vatera’s other portfolio companies include Rib-X Pharmaceuticals, which raised a $67.5m Series 2 round in November 2012.
Copyright © 2014 AltAssets